secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cabaletta Bio, Inc. (CABA)
CIK:        0001759138
Form:       8-K
Filed at:   2023-10-02T23:59:59+00:00
Accession:  0001193125-23-248186
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cabaletta Bio receives FDA clearance for third CABA-201 IND, now in systemic sclerosis
--------------------------------------------------------------------------------

- Third IND clearance for CABA-201 (CD19-CAR T) in systemic sclerosis within past 6 months.
- Phase 1/2 trial to enroll two parallel cohorts: severe skin (n=6) and severe organ involvement (n=6).
- Starting dose 1×10^6 cells/kg, same as lupus and myositis trials; three-month data expected by H1 2024.
- SSc affects ~88,000 US patients; average survival ~12 years after diagnosis with limited treatments.
- Trial part of CARTA strategy aiming to reset immune system via transient B-cell elimination.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759138/000119312523248186/0001193125-23-248186-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759138/000119312523248186/d513135d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-248186

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer